Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - Cervarix, December 11, 2007

(System Info - 107579 SHONE DEANNA 10/13/2009 17:25:23 SHONEDE)


Submission Type:    BLA    Submission ID:  125259/0        Office:  OVRR


 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant


GlaxoSmithKline Biologicals  

 Telecon Date/Time:  11-Dec-2007 12:00 AM            Initiated by FDA? Yes                                           

Telephone Number:                                                                      

Communication Categorie(s):                              

1. Advice                                             

Author:                     MANETTE NIU

Brief Description:           

Clarification of 08/21/07 Pharmacovigilance Comments

FDA Participants:            

Non-FDA Participant(s):      

Trans-BLA Group :                 No                           

Related STNS :               

Related PMCs :               

Telecon Body:                

Sent: Tuesday, December 11, 2007 1:03 PM

To: ''

Cc: ''

Subject: RE: CBER's Aug 21 Pharmacovigilance Comments - Clarification


This sentence does read must better. I hope this helps to clarify your question.

Response to #3a:

The agency is requesting VAERS forms (for domestic reports), and CIOMS forms (international reports) for serious-expected, and non-serious-unexpected adverse event reports at each othese monthly periodic reports.

The agency is not specifically requesting nonserious-expected adverse event reports from outside the U.S.

Please include as 15 day reports: All of the following adverse events whether or not they meet the regulation requirements for serious, including neuroinflammatory diseases (transverse myelitis, multiple sclerosis, optic neuritis, GBS), autoimmune diseases (rheumatoid arthritis, SLE), thrombotic events (deep venous thrombosis, pulmonary emboli), thrombocytopenia, seizure, syncope, spontaneous abortion, congenital birth defects (including ventricular septal defects).

As 30 day (monthly reports): All adverse event reports of arthritis, arthralgia, arthropathy, proteinuria whether or not they meet the regulation requirements for serious.

Page Last Updated: 04/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English